Stryker (NYSE:SYK) updated its second quarter 2019 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.90-1.95 for the period, compared to the Thomson Reuters consensus estimate of $1.96. Stryker also updated its FY 2019 guidance to $8.05-8.20 EPS.
SYK has been the topic of several recent research reports. Zacks Investment Research upgraded Stryker from a hold rating to a buy rating and set a $209.00 price target on the stock in a report on Thursday. Canaccord Genuity upped their price objective on Stryker from $190.00 to $195.00 and gave the company a buy rating in a research report on Wednesday. Deutsche Bank upped their price objective on Stryker from $181.00 to $208.00 and gave the company a buy rating in a research report on Wednesday. Cantor Fitzgerald upped their price objective on Stryker from $175.00 to $190.00 and gave the company a neutral rating in a research report on Wednesday. Finally, Robert W. Baird upped their price objective on Stryker from $201.00 to $206.00 and gave the company an outperform rating in a research report on Wednesday. Seven research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Stryker currently has a consensus rating of Buy and a consensus target price of $196.44.
Shares of SYK traded up $0.92 during midday trading on Thursday, reaching $185.96. 768,649 shares of the stock were exchanged, compared to its average volume of 1,352,649. Stryker has a 52 week low of $144.75 and a 52 week high of $199.85. The company has a current ratio of 2.02, a quick ratio of 1.41 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $69.76 billion, a price-to-earnings ratio of 25.44, a PEG ratio of 2.27 and a beta of 0.88.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Stryker had a return on equity of 27.58% and a net margin of 25.38%. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.68 EPS. On average, equities research analysts predict that Stryker will post 8.13 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date of this dividend is Thursday, March 28th. Stryker’s dividend payout ratio (DPR) is currently 28.45%.
In other Stryker news, Chairman Kevin Lobo sold 41,750 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $194.11, for a total value of $8,104,092.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 180 shares of the stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $176.77, for a total value of $31,818.60. The disclosure for this sale can be found here. Insiders have sold a total of 130,455 shares of company stock valued at $24,723,292 over the last 90 days. 7.20% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Stryker (SYK) Issues Q2 2019 Earnings Guidance” was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://macondaily.com/2019/04/25/stryker-syk-issues-q2-2019-earnings-guidance.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
See Also: What is a Reverse Stock Split?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.